Isolation and mutagenesis of a capsule-like complex (CLC) from francisella tularensis, and contribution of the CLC to F. tularensis virulence in mice

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Bandara, Aloka B ^a   Champion, Anna E ^a   Wang, Xiaoshan ^a,d   Berg, Gretchen ^a,e   Apicella, Michael A ^b   McLendon, Molly ^b   Azadi, Parastoo ^c   Snyder, D Scott ^c   Inzana, Thomas J ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d Biochain   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CAPSULE LIKE COMPLEX ANTIGEN; GLYCOSYLTRANSFERASE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; GLYCOPROTEIN; VIRULENCE FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PURIFICATION; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CARBOHYDRATE SYNTHESIS; CELL VIABILITY; CONTROLLED STUDY; FRANCISELLA TULARENSIS; GENE EXPRESSION; GENE IDENTIFICATION; MACROPHAGE; MOLECULAR SIZE; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; ELECTRON MICROSCOPY; GENETICS; ISOLATION AND PURIFICATION; MASS FRAGMENTOGRAPHY; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TULAREMIA; ULTRASTRUCTURE;

ANIMALIA; FRANCISELLA TULARENSIS; MUS;

ANIMALS; FRANCISELLA TULARENSIS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCOPROTEINS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; POLYSACCHARIDES, BACTERIAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TULAREMIA; VIRULENCE FACTORS;

EID: 79955527898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019003     Document Type: Article

References (61)

1. Ellis J, Oyston PC, Green M, Titball RW, (2002) Tularemia. Clin Microbiol Rev 15: 631-646.
2. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773.
3. Staples JE, Kubota KA, Chalcraft LG, Mead PS, Petersen JM, (2006) Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004. Emerg Infect Dis 12: 1113-1118.
4. Penn RL, (2005) Francisella tularensis (Tularemia). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principals and Practice of Infectious Diseases. 6th ed Philadelphia Elsevier Churchill Livingstone pp. 2674-2685.
5. Tigertt WD, (1962) Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev 26: 354-373.
6. Conlan J, Oyston P, (2007) Vaccines against Francisella tularensis. Ann N Y Acad Sci 1105: 325-350.
7. Conlan JW, (2004) Vaccines against Francisella tularensis-past, present and future. Expert Rev Vaccines 3: 307-314.
8. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA, (1991) Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 59: 2922-2928.
9. McCoy GW, Chapin CW, (1912) Further observations on a plague-like diseases of rodents with a preliminary note on the causative agent, Bacterium tularensis. J Infect Dis 10: 61-72.
10. Hartley G, Taylor R, Prior J, Newstead S, Hitchen PG, et al. (2006) Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice. Vaccine 24: 989-996.
11. Li J, Ryder C, Mandal M, Ahmed F, Azadi P, et al. (2007) Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiol 153: 3141-3153.
12. Raynaud C, Meibom KL, Lety MA, Dubail I, Candela T, et al. (2007) Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect Immun 75: 536-541.
13. Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, et al. (2007) A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun 75: 2591-2602.
14. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, et al. (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A 106: 4343-4348.
15. Dreisbach VC, Cowley S, Elkins KL, (2000) Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 68: 1988-1996.
16. Conlan JW, Shen H, Webb A, Perry MB, (2002) Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465-3471.
17. Thomas RM, Titball RW, Oyston PC, Griffin K, Waters E, et al. (2007) The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun 75: 371-378.
18. Fulop M, Manchee R, Titball R, (1996) Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol Med Microbiol 13: 245-247.
19. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664-3671.
20. McLendon MK, Apicella MA, Allen LA, (2006) Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol 60: 167-185.
21. Sandström G, Löfgren S, Tärnvik A, (1988) A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect Immun 56: 1194-1202.
22. Sjöstedt A, (2005) Family III. Francisellaceae, fam. nov. In: Brenner NRK DJ, Staley JT, editors. Bergey's Manual of Systematic Bacteriology second edition New York Springer pp. 199-210.
23. Sorokin VM, Pavlovich NV, Prozorova LA, (1996) Francisella tularensis resistance to bactericidal action of normal human serum. FEMS Immunol Med Microbiol 13: 249-252.
24. Clemens DL, Horwitz MA, (2007) Uptake and intracellular fate of Francisella tularensis in human macrophages. Ann N Y Acad Sci 1105: 160-186.
25. Clemens DL, Lee BY, Horwitz MA, (2005) Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun 73: 5892-5902.
26. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A, (2003) An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect Immun 71: 5940-5950.
27. Cherwonogrodzky JW, Knodel MH, Spence MR, (1994) Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium. Vaccine 12: 773-775.
28. Hood AM, (1977) Virulence factors of Francisella tularensis. J Hyg (Lond) 79: 47-60.
29. Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, et al. (2010) Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. PLoS One 5: e11060.
30. Lindemann SR, Peng K, Long ME, Hunt JR, Apicella MA, et al. (2011) Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages. Infect Immun 79: 581-594.
31. Prior JL, Prior RG, Hitchen PG, Diaper H, Griffin KF, et al. (2003) Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol 52: 845-851.
32. Larsson P, Oyston PC, Chain P, Chu MC, Duffield M, et al. (2005) The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet 37: 153-159.
33. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M, (1989) Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 171: 722-730.
34. Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, et al. (2010) Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 28: 1824-1831.
35. Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, et al. (2010) A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect Immun 78: 4341-4355.
36. Michell SL, Dean RE, Eyles JE, Hartley MG, Waters E, et al. (2010) Deletion of the Bacillus anthracis capB homologue in Francisella tularensis subspecies tularensis generates an attenuated strain that protects mice against virulent tularaemia. J Med Microbiol 59: 1275-1284.
37. Su J, Yang J, Zhao D, Kawula TH, Banas JA, et al. (2007) Genome-wide identification of Francisella tularensis virulence determinants. Infect Immun 75: 3089-3101.
38. Alkhuder K, Meibom KL, Dubail I, Dupuis M, Charbit A, (2009) Glutathione provides a source of cysteine essential for intracellular multiplication of Francisella tularensis. PLoS Pathog 5: e1000284.
39. Maier TM, Havig A, Casey M, Nano FE, Frank DW, et al. (2004) Construction and characterization of a highly efficient Francisella shuttle plasmid. Appl Environ Microbiol 70: 7511-7519.
40. Messner P, Steiner K, Zarschler K, Schaffer C, (2008) S-layer nanoglycobiology of bacteria. Carbohydr Res 343: 1934-1951.
41. Anderson P, Pitt J, Smith DH, (1976) Synthesis and release of polyribophosphate by Haemophilus influenzae type b in vitro. Infect Immun 13: 581-589.
42. Balonova L, Hernychova L, Mann BF, Link M, Bilkova Z, et al. (2010) Multimethodological approach to identification of glycoproteins from the proteome of Francisella tularensis, an intracellular microorganism. J Proteome Res 9: 1995-2005.
43. DeShazer D, Waag DM, Fritz DL, Woods DE, (2001) Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb Pathog 30: 253-269.
44. Ward CK, Inzana TJ, (1997) Identification and characterization of a DNA region involved in the export of capsular polysaccharide by Actinobacillus pleuropneumoniae serotype 5a. Infect Immun 65: 2491-2496.
45. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, et al. (2007) In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci U S A 104: 6037-6042.
46. Green M, Choules G, Rogers D, Titball RW, (2005) Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine 23: 2680-2686.
47. Dubois M, Hamilton, A, Rebers, PA, Smith, F, (1956) Colorimetric method for determination of sugars and related substances. Anal Chem 28: 350-356.
48. Karkhanis Y, Zeltner, JA, Jackson, JJ, Carlo, DJ, (1978) A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria. Anal Biochem 85: 595-601.
49. Merkle RK, Poppe I, (1994) Carbohydrate composition analysis of glycoconjugates by gas-liquid chromatography/mass spectrometry. Methods Enzymol 230: 1-15.
50. Goldberg HA, Warner KJ, (1997) The staining of acidic proteins on polyacrylamide gels: enhanced sensitivity and stability of "Stains-all" staining in combination with silver nitrate. Anal Biochem 251: 227-233.
51. Inzana TJ, Glindemann GE, Snider G, Gardner S, Crofton L, et al. (2004) Characterization of a wildtype strain of Francisella tularensis isolated from a cat. J Vet Diagn Invest 16: 374-381.
52. Ward CK, Inzana TJ, (1994) Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide. J Immunol 153: 2110-2121.
53. Altschul S, Gish W, Miller W, Myers EW, Lipman DJ, (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
54. Smith TF, Waterman MS, (1981) Identification of common molecular subsequences. J Mol Biol 147: 195-197.
55. Sambrook J, Fritsch EF, Maniatis T, (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor, N.Y. Cold Spring Harbor Laboratory.
56. Ried JL, Collmer A, (1987) An nptI-sacB-sacR cartridge for constructing directed, unmarked mutations in gram-negative bacteria by marker exchange-eviction mutagenesis. Gene 57: 239-246.
57. Pavlov VM, Mokrievich AN, Volkovoy K, (1996) Cryptic plasmid pFNL10 from Francisella novicida-like F6168: the base of plasmid vectors for Francisella tularensis. FEMS Immunol Med Microbiol 13: 253-256.
58. Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, et al. (1995) Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166: 175-176.
59. Inzana TJ, Anderson P, (1985) Serum factor-dependent resistance of Haemophilus influenzae type b to antibody to lipopolysaccharide. J Infect Dis 151: 869-877.
60. Cowley SC, Elkins KL, (2003) Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med 198: 379-389.
61. Ott LR, (1993) An Introduction to Statistical Analysis. Fourth edition Duxbury Press pp. 260-290.